Hospital
Monroe Health Services, INC.
Monroe Health Services, INC. was paid $16.44M by Medicaid between Dec 2018 and Dec 2024, across 181 billing codes. Its largest line is 99284, emergency room visit (serious) — 21% of everything it billed.
33Billing provider infoMONROE HEALTH SERVICES, INC.
AMORY, MS 38821
AMORY, MS 38821
33aNPI1164993457assigned 12/11/2018
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.44M
24GClaims357,090
24DCodes billed181
24AFirst – last monthDec 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#31 of 77
Median peer was paid$8.23M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TOPPIN, BRUCE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,276 | $104K | |
| 2019 | 54,904 | $2.32M | |
| 2020 | 43,361 | $1.67M | |
| 2021 | 61,275 | $2.88M | |
| 2022 | 67,299 | $3.49M | |
| 2023 | 71,531 | $3.32M | |
| 2024incomplete | 56,444 | $2.64M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 17,612 | 14,933 | $3.53M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 20,307 | 17,013 | $2.86M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.1% | 6,413 | 5,511 | $1.49M |
| G0378 | Hospital observation service, per hour | 8.6% | 3,027 | 2,403 | $1.41M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.5% | 7,590 | 6,216 | $740K |
| 87428 | 3.1% | 9,625 | 8,549 | $514K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2.6% | 4,057 | 2,201 | $422K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.5% | 6,908 | 4,888 | $417K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 2,209 | 1,935 | $372K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.2% | 8,827 | 6,776 | $356K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 3,537 | 2,852 | $342K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.0% | 3,090 | 1,282 | $323K |
169 more codes
| 71045 | Radiologic examination, chest; single view | 1.9% | 7,500 | $312K |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | 1.8% | 990 | $290K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 1,758 | $186K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 3,927 | $170K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 6,168 | $166K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,140 | $153K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,739 | $149K |
| D7240 | Removal of impacted tooth - completely bony | <1% | 234 | $109K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,212 | $101K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,293 | $100K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,227 | $100K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 7,657 | $99K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,332 | $97K |
| 80053 | Comprehensive metabolic panel | <1% | 15,803 | $97K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 968 | $93K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,813 | $90K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 931 | $69K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 1,807 | $58K |
| 86900 | <1% | 935 | $51K | |
| 87400 | <1% | 3,771 | $48K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 887 | $44K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 832 | $42K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,549 | $40K |
| 97597 | <1% | 837 | $39K | |
| 87807 | <1% | 3,238 | $36K | |
| 87430 | <1% | 2,592 | $32K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,054 | $32K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 163 | $31K |
| 74018 | <1% | 591 | $30K | |
| 87081 | <1% | 5,331 | $28K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 692 | $28K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,430 | $27K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 607 | $27K |
| 73630 | <1% | 606 | $27K | |
| 81001 | <1% | 12,818 | $26K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 89 | $23K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 356 | $22K |
| 87070 | <1% | 3,021 | $22K | |
| 86885 | <1% | 325 | $22K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 441 | $21K |
| 84484 | <1% | 3,544 | $20K | |
| 81025 | <1% | 3,380 | $20K | |
| 83880 | <1% | 1,496 | $20K | |
| C9399 | Unclassified drugs or biologicals | <1% | 1,048 | $20K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 618 | $18K |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,246 | $18K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 520 | $18K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 70 | $18K |
| 74019 | <1% | 244 | $16K | |
| 83690 | <1% | 3,991 | $16K | |
| 86901 | <1% | 965 | $16K | |
| 73610 | <1% | 346 | $16K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 58 | $16K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 261 | $14K |
| 31720 | <1% | 104 | $14K | |
| 73030 | <1% | 381 | $14K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 114 | $14K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 205 | $14K |
| 87040 | <1% | 2,523 | $13K | |
| 80306 | <1% | 1,050 | $13K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,044 | $11K |
| 84703 | <1% | 1,966 | $11K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 798 | $10K |
| 73562 | <1% | 236 | $9K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 53 | $8K |
| D2931 | <1% | 139 | $8K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 488 | $8K |
| 84702 | <1% | 715 | $8K | |
| 87186 | <1% | 1,158 | $7K | |
| 87077 | <1% | 1,216 | $7K | |
| 83605 | <1% | 1,429 | $7K | |
| 73130 | <1% | 181 | $7K | |
| 83735 | <1% | 1,885 | $6K | |
| 87420 | <1% | 568 | $6K | |
| 80061 | Lipid panel | <1% | 651 | $5K |
| 59025 | Fetal non-stress test | <1% | 44 | $5K |
| 72100 | <1% | 110 | $5K | |
| 73110 | <1% | 111 | $5K | |
| 82248 | <1% | 1,080 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 90 | $4K |
| 82247 | <1% | 1,061 | $4K | |
| 86140 | <1% | 1,214 | $4K | |
| 82962 | <1% | 2,332 | $4K | |
| 74021 | <1% | 59 | $3K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 22 | $3K |
| 85610 | <1% | 1,289 | $3K | |
| 86769 | <1% | 66 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,037 | $2K |
| 76801 | <1% | 27 | $2K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 30 | $2K |
| 85730 | <1% | 573 | $2K | |
| 36600 | <1% | 57 | $1K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 15 | $1K |
| 12001 | <1% | 15 | $1K | |
| D2394 | <1% | 16 | $1K | |
| 87205 | <1% | 530 | $1K | |
| 81003 | <1% | 636 | $1K | |
| 97162 | <1% | 30 | $1K | |
| 82550 | <1% | 398 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 14 | $1K |
| 85027 | <1% | 244 | $1K | |
| 88304 | <1% | 31 | $977.78 | |
| 85379 | <1% | 224 | $923.87 | |
| 83655 | <1% | 96 | $910.46 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,401 | $878.77 |
| 96367 | <1% | 31 | $862.81 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 155 | $836.93 |
| 85652 | <1% | 511 | $763.76 | |
| 73080 | <1% | 20 | $757.80 | |
| 86677 | <1% | 99 | $738.55 | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 20 | $641.97 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 15 | $537.25 |
| J3490 | Unclassified drugs | <1% | 1,324 | $517.11 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 114 | $486.57 |
| 82803 | <1% | 62 | $471.35 | |
| 86850 | <1% | 12 | $416.36 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,136 | $411.65 |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 31 | $367.68 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,849 | $297.62 |
| 82150 | <1% | 61 | $286.90 | |
| 82728 | <1% | 32 | $276.48 | |
| 84550 | <1% | 75 | $235.47 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,712 | $227.68 |
| A9270 | Non-covered item or service | <1% | 2,622 | $226.61 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,286 | $205.95 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,158 | $199.64 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 18 | $195.20 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,362 | $186.00 |
| 82553 | <1% | 34 | $143.58 | |
| 83874 | <1% | 34 | $139.92 | |
| 83615 | <1% | 35 | $131.26 | |
| 90714 | <1% | 220 | $124.24 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,518 | $116.47 |
| 80076 | <1% | 13 | $97.92 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,405 | $82.87 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 447 | $68.32 |
| 82607 | <1% | 16 | $68.27 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,527 | $67.36 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 619 | $62.42 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,074 | $32.53 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,406 | $31.56 |
| 84100 | <1% | 15 | $29.20 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,199 | $27.28 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 979 | $26.79 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 172 | $25.72 |
| 80305 | <1% | 18 | $22.68 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,463 | $18.50 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 324 | $13.30 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 815 | $10.68 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 621 | $9.30 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 112 | $0.67 |
| 80050 | General health panel | 0% | 13 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 334 | $0.00 |
| 96376 | 0% | 2,014 | $0.00 | |
| 36416 | 0% | 291 | $0.00 | |
| 80349 | 0% | 51 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 115 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 26 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 36 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 26 | $0.00 |
| 94760 | 0% | 15 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 26 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 202 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 41 | $0.00 |
| 84145 | 0% | 133 | $0.00 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 157 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 20 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 287 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 123 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTOPPIN, BRUCE (CORPORATE SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.